California Passes Telemedicine Law

20 January 1997

Under a new law in California, private-sector health care providers mustestablish, by July 1, reimbursement for telemedicine procedures considered equivalent to face-to-face visits.

Feedback Research Services, which has published a report on the issue, says there was relatively little objection from the health care industry to the bill, which is seen as a model for demonstrating the power of cooperation and education betwewn industry and legislators.

The focus has been on federally- and state-funded programs (Marketletter January 13), there may be 10 times as many total systems in use when privately-funded telemedicine networks are included, FBS says. Also, the barriers associated with reimbursement may ultimately not be of concern to doctors and health care providers, some of whom already bill for telemedicine-mediated services as regular visits.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight